Studie Arthritis (Reuma) / Osteoporose

Post Menopausal Osteoporosis — Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Post Menopausal Osteoporosis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Post Menopausal Osteoporosis, complete with latest updates, and special features on late-stage and discontinued proje... mehr

Sarcopenia — Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Sarcopenia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Sarcopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the thera... mehr

Cachexia — Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Cachexia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic... mehr

Fracture — Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Fracture - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Fracture, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic... mehr

Multiple Sclerosis — Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Multiple Sclerosis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Multiple Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key playe... mehr

Psoriatic Arthritis — Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Psoriatic Arthritis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Psoriatic Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key pl... mehr

Renal Anemia — Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Renal Anemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Renal Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the... mehr

Rheumatoid Arthritis — Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Rheumatoid Arthritis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key... mehr

Actonel (Osteoporosis) - Forecast and Market Analysis to 2022


Summary


GlobalData has released its new PharmaPoint Drug Evaluation report, 'Actonel (Osteoporosis) - Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by e... mehr

Ankylosing Spondylitis (Bekhterev's Disease) — Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease), complete with latest updates, and speci... mehr

Aprela (Osteoporosis) - Forecast and Market Analysis to 2022


Summary


GlobalData has released its new PharmaPoint Drug Evaluation report, 'Aprela (Osteoporosis) - Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end... mehr

Arthritis — Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Arthritis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeu... mehr

BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022


Summary


GlobalData has released its new PharmaPoint Drug Evaluation report, 'BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end... mehr

Bone Disorders — Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Bone Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bone Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ... mehr

Evista (Osteoporosis) - Forecast and Market Analysis to 2022


Summary


GlobalData has released its new PharmaPoint Drug Evaluation report, 'Evista (Osteoporosis) - Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end... mehr

Forteo (Osteoporosis) - Forecast and Market Analysis to 2022


Summary


GlobalData has released its new PharmaPoint Drug Evaluation report, 'Forteo (Osteoporosis) - Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end... mehr

Muscle Wasting Disorders — Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Muscle Wasting Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Muscle Wasting Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also... mehr

Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022


Summary


GlobalData has released its new PharmaPoint Drug Evaluation report, 'Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protectio... mehr

Ostora (Osteoporosis) - Forecast and Market Analysis to 2022


Summary


GlobalData has released its new PharmaPoint Drug Evaluation report, 'Ostora (Osteoporosis) - Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end... mehr

PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022


Summary


GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protect... mehr

PharmaPoint: Osteoporosis - Current and Future Players


Summary


Osteoporosis is caused by the gradual weakening of the bones due to abnormal osteocyte function, which occurs as a result of hormonal fluctuations, vitamin deficiency, or aging, and leads to reduced mobility and/or bone fractures.

GlobalData has released its pharma report, 'PharmaPoint: Osteoporosis - Current and Future Players”... mehr

PharmaPoint: Osteoporosis - France Drug Forecast and Market Analysis to 2022


Summary


GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - France Drug Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent prote... mehr

PharmaPoint: Osteoporosis - Germany Drug Forecast and Market Analysis to 2022


Summary


GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - Germany Drug Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent pro... mehr

PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022


Summary


GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protect... mehr

PharmaPoint: Osteoporosis - Italy Drug Forecast and Market Analysis to 2022


Summary


GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - Italy Drug Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protect... mehr

PharmaPoint: Osteoporosis - Japan Drug Forecast and Market Analysis to 2022


Summary


GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - Japan Drug Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protect... mehr

PharmaPoint: Osteoporosis - Spain Drug Forecast and Market Analysis to 2022


Summary


GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - Spain Drug Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protect... mehr

PharmaPoint: Osteoporosis - UK Drug Forecast and Market Analysis to 2022


Summary


GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - UK Drug Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by... mehr

PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022


Summary


GlobalData has released its new Country report, 'PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by... mehr

Protelos (Osteoporosis) - Forecast and Market Analysis to 2022


Summary


GlobalData has released its new PharmaPoint Drug Evaluation report, 'Protelos (Osteoporosis) - Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by... mehr

PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022


Summary


GlobalData has released its new PharmaPoint Drug Evaluation report, 'PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent prote... mehr

Recalbon/Bonoteo (Osteoporosis) - Forecast and Market Analysis to 2022


Summary


GlobalData has released its new PharmaPoint Drug Evaluation report, 'Recalbon/Bonoteo (Osteoporosis) - Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose pate... mehr

Reclast (Osteoporosis) - Forecast and Market Analysis to 2022


Summary


GlobalData has released its new PharmaPoint Drug Evaluation report, 'Reclast (Osteoporosis) - Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by e... mehr

Romosozumab (Osteoporosis) - Forecast and Market Analysis to 2022


Summary


GlobalData has released its new PharmaPoint Drug Evaluation report, 'Romosozumab (Osteoporosis) - Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protect... mehr

Viviant/Combriza (Osteoporosis) - Forecast and Market Analysis to 2022


Summary


GlobalData has released its new PharmaPoint Drug Evaluation report, 'Viviant/Combriza (Osteoporosis) - Forecast and Market Analysis to 2022”. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose pate... mehr

Cachexia Global Clinical Trials Review, H1, 2013


Summary


GlobalData's clinical trial report, 'Cachexia Global Clinical Trials Review, H1, 2013' provides data on the Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction ... mehr

Cancer Cachexia Global Clinical Trials Review, H1, 2013


Summary


GlobalData's clinical trial report, 'Cancer Cachexia Global Clinical Trials Review, H1, 2013' provides data on the Cancer Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Cachexia. It includes an overview of the trial numbers and their recruitment status as per t... mehr

Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion


Summary


GBI Research, the leading business intelligence provider, has released its latest research, 'Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimil... mehr

EpiCast Report: Osteoporosis - Epidemiology Forecast to 2022


Summary


The lifetime risk of osteoporotic fracture is 50% in women and 10%—30% in men (Randell et al., 1995). The morbidity and mortality associated with osteoporotic fractures make osteoporosis a global health burden, second only to cardiovascular disease (Woolf, 2000). Over the next decade, there will be a 26.8% increase in the prevale... mehr

Muscular Dystrophy — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Muscular Dystrophy - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Muscular Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key playe... mehr

Rheumatology Therapeutics Market to 2018 - Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth


Summary


GBI Research, the leading business intelligence provider, has released its latest research, 'Rheumatology Therapeutics Market to 2018 - Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth”. The report prov... mehr

Cancer Cachexia — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Cancer Cachexia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cancer Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involv... mehr

Fibrosis — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Fibrosis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic... mehr

Intermittent Claudication — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Intermittent Claudication - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Intermittent Claudication, complete with latest updates, and special features on late-stage and discontinued projects. It a... mehr

Osteonecrosis — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Osteonecrosis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Osteonecrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in ... mehr

Psoriatic Arthritis Global Clinical Trials Review, H2, 2012


Summary


GlobalData's clinical trial report, 'Psoriatic Arthritis Global Clinical Trials Review, H2, 2012' provides data on the Psoriatic Arthritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Psoriatic Arthritis. It includes an overview of the trial numbers and their recruitment... mehr

Sarcopenia — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Sarcopenia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Sarcopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the thera... mehr

Systemic Juvenile Idiopathic Arthritis (SJIA) — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Systemic Juvenile Idiopathic Arthritis (SJIA), complete with latest updates, and sp... mehr

Cachexia — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Cachexia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic... mehr

Fracture — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Fracture - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Fracture, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic... mehr

Osteonecrosis Global Clinical Trials Review, H2, 2012


Summary


GlobalData's clinical trial report, 'Osteonecrosis Global Clinical Trials Review, H2, 2012' provides data on the Osteonecrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Osteonecrosis. It includes an overview of the trial numbers and their recruitment status as per the site ... mehr

Psoriatic Arthritis — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Psoriatic Arthritis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Psoriatic Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key pl... mehr

Autoimmune Disorders — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Autoimmune Disorders - Pipeline Review, H2 2012', provides an overview of the Autoimmune Disorders therapeutic pipeline. This report provides information on the therapeutic development for Autoimmune Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also revie... mehr

Osteoarthritis — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Osteoarthritis - Pipeline Review, H2 2012', provides an overview of the Osteoarthritis therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ... mehr

Osteoporosis Global Clinical Trials Review, H2, 2012


Summary


GlobalData's clinical trial report, 'Osteoporosis Global Clinical Trials Review, H2, 2012' provides data on the Osteoporosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Osteoporosis. It includes an overview of the trial numbers and their recruitment status as per the site of t... mehr

Osteoporosis — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Osteoporosis - Pipeline Review, H2 2012', provides an overview of the Osteoporosis therapeutic pipeline. This report provides information on the therapeutic development for Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the t... mehr

Other Musculoskeletal Disorders — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Other Musculoskeletal Disorders - Pipeline Review, H2 2012', provides an overview of the Other Musculoskeletal Disorders therapeutic pipeline. This report provides information on the therapeutic development for Other Musculoskeletal Disorders, complete with latest updates, and special features on late-st... mehr

Rheumatic Disorders — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Rheumatic Disorders - Pipeline Review, H2 2012', provides an overview of the Rheumatic Disorders therapeutic pipeline. This report provides information on the therapeutic development for Rheumatic Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews k... mehr

Rheumatoid Arthritis — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Rheumatoid Arthritis - Pipeline Review, H2 2012', provides an overview of the Rheumatoid Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also revie... mehr

Ankylosing Spondylitis (Bekhterev's Disease) — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2012', provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) therapeutic pipeline. This report provides information on the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease), complete ... mehr

Arthritis — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Arthritis - Pipeline Review, H2 2012', provides an overview of the Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic d... mehr

Muscle Wasting Disorders — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Muscle Wasting Disorders - Pipeline Review, H2 2012', provides an overview of the Muscle Wasting Disorders therapeutic pipeline. This report provides information on the therapeutic development for Muscle Wasting Disorders, complete with latest updates, and special features on late-stage and discontinued project... mehr

Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar


Summary


GBI Research, the leading business intelligence provider, has released its latest research, 'Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Lau... mehr

Muscle Spasm — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Muscle Spasm - Pipeline Review, H1 2012', provides an overview of the Muscle Spasm therapeutic pipeline. This report provides information on the therapeutic development for Muscle Spasm, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the t... mehr

Muscular Dystrophy — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Muscular Dystrophy - Pipeline Review, H1 2012', provides an overview of the Muscular Dystrophy therapeutic pipeline. This report provides information on the therapeutic development for Muscular Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key p... mehr

Ankylosing Spondylitis (Bekhterev’s Disease) Global Clinical Trials Review, H1, 2012


Summary


GlobalData's clinical trial report, 'Ankylosing Spondylitis (Bekhterev’s Disease) Global Clinical Trials Review, H1, 2012' provides data on the Ankylosing Spondylitis (Bekhterev’s Disease) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ankylo... mehr

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications


Summary


GBI Research’s new report, 'Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications”, provides a... mehr

Cancer Cachexia — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Cancer Cachexia - Pipeline Review, H1 2012', provides an overview of the Cancer Cachexia therapeutic pipeline. This report provides information on the therapeutic development for Cancer Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players invol... mehr

TechNavio’s analysts forecast the Global Musculoskeletal Drugs market to grow at a CAGR of 14.4 percent over the period 2011—2015. One of the key factors contributing to this market growth is the increasing prevalence of musculoskeletal diseases. The Global Musculoskeletal Drugs market has also been witnessing the increasing use of drugs for treatment of multiple diseases. However, the upcoming patent expiries of top-selling dru... mehr

Intermittent Claudication — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Intermittent Claudication - Pipeline Review, H1 2012', provides an overview of the Intermittent Claudication therapeutic pipeline. This report provides information on the therapeutic development for Intermittent Claudication, complete with latest updates, and special features on late-stage and discontinued pro... mehr

Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments


Summary


GBI Research, the leading business intelligence provider, has released its latest research 'Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and ... mehr

TechNavio’s analysts forecast the Rheumatoid Arthritis market in Japan to grow at a CAGR of 29.2 percent over the period 2011—2015. One of the key factors contributing to this market growth is the high prevalence rate of patients suffering from rheumatoid arthritis. The Rheumatoid Arthritis Drugs market in Japan has also been witnessing a trend of increasing number of collaborations among vendors. However, stringent regulatory r... mehr

Sarcopenia — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Sarcopenia - Pipeline Review, H1 2012', provides an overview of the Sarcopenia therapeutic pipeline. This report provides information on the therapeutic development for Sarcopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeut... mehr

Systemic Juvenile Idiopathic Arthritis (SJIA) — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H1 2012', provides an overview of the Systemic Juvenile Idiopathic Arthritis (SJIA) therapeutic pipeline. This report provides information on the therapeutic development for Systemic Juvenile Idiopathic Arthritis (SJIA), compl... mehr

Analgesics maintained its positive development in 2011, with most categories showing robust growth in volume and current value terms. This performance was underpinned by the strong tendency of Bolivians to self-medicate for minor ailments such as headaches, joint and muscle pain and cough, cold and flu symptoms. This tendency is partly due to the fact that most Bolivians live on low incomes and cannot afford to visit the doctor for such... mehr

Systemic analgesics remain the most popular OTC analgesics type on the Bulgarian market, and the most popular product among them is Analgin, which has been a favourite of Bulgarians since its launch in 1954. Furthermore, for years it was the only systemic analgesic product on the market, therefore even when competitive products became available, Analgin remained the most often purchased among them.

Euromonitor International's... mehr

Cachexia — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Cachexia - Pipeline Review, H1 2012', provides an overview of the Cachexia therapeutic pipeline. This report provides information on the therapeutic development for Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic devel... mehr

Fracture — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Fracture - Pipeline Review, H1 2012', provides an overview of the Fracture therapeutic pipeline. This report provides information on the therapeutic development for Fracture, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic devel... mehr

Osteopenia — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Osteopenia - Pipeline Review, H1 2012', provides an overview of the Osteopenia therapeutic pipeline. This report provides information on the therapeutic development for Osteopenia , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeu... mehr

Arthritis Global Clinical Trials Review, H1, 2012

Summary

GlobalData's clinical trial report, 'Arthritis Global Clinical Trials Review, H1, 2012' provides data on the Arthritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Arthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across t... mehr

Cachexia Global Clinical Trials Review, H1, 2012

Summary

GlobalData's clinical trial report, 'Cachexia Global Clinical Trials Review, H1, 2012' provides data on the Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the g... mehr

Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success

Summary

GBI Research, the leading business intelligence provider, has released its latest research, 'Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success” which provides an insight ... mehr

Gouty Arthritis (Gout) — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Gouty Arthritis (Gout) - Pipeline Review, H1 2012', provides an overview of the Gouty Arthritis (Gout) therapeutic pipeline. This report provides information on the therapeutic development for Gouty Arthritis (Gout), complete with latest updates, and special features on late-stage and discontinued projects. It al... mehr

Graves’ Disease Therapeutics - Pipeline Assessment and Market Forecast to 2019


Summary


GlobalData, the industry analysis specialist, has released its new report, 'Graves’ Disease Therapeutics - Pipeline Assessment and Market Forecast to 2019”. The report is an essential source of information and analysis on the global Graves Disease Therapeutics market. The report identifies the key trends shaping... mehr

Osteoarthritis — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Osteoarthritis - Pipeline Review, H1 2012', provides an overview of the Osteoarthritis therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ... mehr

Osteoporosis — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Osteoporosis - Pipeline Review, H1 2012', provides an overview of the Osteoporosis therapeutic pipeline. This report provides information on the therapeutic development for Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the t... mehr

Psoriatic Arthritis — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Psoriatic Arthritis - Pipeline Review, H1 2012', provides an overview of the Psoriatic Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Psoriatic Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews k... mehr

Ankylosing Spondylitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Ankylosing Spondylitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Ankylosing Spondylitis Therapeutics market. The report identifies the key trends... mehr

Arthritis — Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Arthritis - Pipeline Review, H1 2012', provides an overview of the Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development f... mehr

Muscle Wasting Disorders — Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Muscle Wasting Disorders - Pipeline Review, H1 2012', provides an overview of the Muscle Wasting Disorders therapeutic pipeline. This report provides information on the therapeutic development for Muscle Wasting Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also r... mehr

Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014

Summary

GBI Research, the leading business intelligence provider, has released its latest report, 'Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014”. The report is built using data and information sourced from... mehr

Crohn’s Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Crohn’s Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Crohn’s Disease Therapeutics market. The report identifies the key trends shap... mehr

Dystonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Dystonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Dystonia Therapeutics market. The report identifies the key trends shaping and driving the global Dystonia T... mehr

Kawasaki Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Kawasaki Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Kawasaki Disease Therapeutics market. The report identifies the key trends shaping and drivi... mehr

Kawasaki Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Kawasaki Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Kawasaki Disease Therapeutics market. The report identifies the key trends shaping and drivi... mehr

Muscle Spasm — Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Muscle Spasm - Pipeline Review, H2 2011', provides an overview of the Muscle Spasm therapeutic pipeline. This report provides information on the therapeutic development for Muscle Spasm, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic d... mehr

Muscular Dystrophy — Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Muscular Dystrophy - Pipeline Review, H2 2011', provides an overview of the Muscular Dystrophy therapeutic pipeline. This report provides information on the therapeutic development for Muscular Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players invol... mehr

Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global osteoporosis therapeutics market. The report identifies the key trends shaping and driving the globa... mehr

Paget’s Disease of Bone (PDB) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Paget’s Disease of Bone (PDB) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global PDB therapeutics market. The report identifies the key trends ... mehr

Thalassemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Thalassemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Thalassemia Therapeutics market. The report identifies the key trends shaping and driving the global T... mehr

Thalassemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Thalassemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Thalassemia Therapeutics market. The report identifies the key trends shaping and driving the global T... mehr

Cancer Cachexia - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Cancer Cachexia - Pipeline Review, H2 2011', provides an overview of the Cancer Cachexia therapeutic pipeline. This report provides information on the therapeutic development for Cancer Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therape... mehr

Crohn’s Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Crohn’s Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Crohn’s Disease Therapeutics market. The report identifies the key trends shap... mehr

Hypercalcemia - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Hypercalcemia - Pipeline Review, H2 2011', provides an overview of the Hypercalcemia therapeutic pipeline. This report provides information on the therapeutic development for Hypercalcemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic dev... mehr

Intermittent Claudication - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Intermittent Claudication - Pipeline Review, H2 2011', provides an overview of the Intermittent Claudication therapeutic pipeline. This report provides information on the therapeutic development for Intermittent Claudication, complete with latest updates, and special features on late-stage and discontinued projects. It also rev... mehr

Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market

Summary

GBI Research’s report, 'Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market” provides in-depth analysis of the drivers and barriers that affect the gl... mehr

Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global osteoarthritis therapeutics market. The report identifies the key trends shaping and d... mehr

Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global osteoarthritis therapeutics market. The report identifies the key trends shaping and driving the... mehr

Osteonecrosis Global Clinical Trials Review, H2, 2011

Summary

GlobalData's clinical trial report, 'Osteonecrosis Global Clinical Trials Review, H2, 2011' provides data on the Osteonecrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Osteonecrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial con... mehr

Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global osteoporosis therapeutics market. The report identifies the key trends shaping and driving the globa... mehr

Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global sarcopenia therapeutics market. The report identifies the key trends shaping and driving the global sarc... mehr

Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Sarcopenia Therapeutics market. The report identifies the key trends shaping and driving the global Sarc... mehr

Cachexia - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Cachexia - Pipeline Review, H2 2011', provides an overview of the Cachexia therapeutic pipeline. This report provides information on the therapeutic development for Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cachexi... mehr

Fracture - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Fracture - Pipeline Review, H2 2011', provides an overview of the Fracture therapeutic pipeline. This report provides information on the therapeutic development for Fracture, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fractur... mehr

Gouty Arthritis (Gout) Global Clinical Trials Review, H2, 2011

Summary

GlobalData's clinical trial report, 'Gouty Arthritis (Gout) Global Clinical Trials Review, H2, 2011' provides data on the Gouty Arthritis (Gout) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gouty Arthritis (Gout) . It includes an overview of the trial numbers and their recruitm... mehr

Osteopenia - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Osteopenia - Pipeline Review, H2 2011', provides an overview of the Osteopenia therapeutic pipeline. This report provides information on the therapeutic development for Osteopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for... mehr

Osteopenia Global Clinical Trials Review, H2 2011

Summary

GlobalData's clinical trial report, 'Osteopenia Global Clinical Trials Review, H2, 2011' provides data on the Osteopenia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Osteopenia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction acros... mehr

Osteoporosis Global Clinical Trials Review, H2, 2011

Summary

GlobalData's clinical trial report, 'Osteoporosis Global Clinical Trials Review, H2, 2011' provides data on the Osteoporosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Osteoporosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduct... mehr

Clinical Trial Recruitment in Autoimmune Disorders-Average Patient Recruitment Per Trial has Continued to Decline Over the Past Decade

Summary

GBI Research, the leading business intelligence provider, has released its latest research 'Clinical Trial Recruitment in Autoimmune Disorders-Average Patient Recruitment per Trial has Continued to Decline Over the Past Decade” which provides an insight into clinical trial... mehr

Gouty Arthritis (Gout) - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Gouty Arthritis (Gout) - Pipeline Review, H2 2011', provides an overview of the Gouty Arthritis (Gout) therapeutic pipeline. This report provides information on the therapeutic development for Gouty Arthritis (Gout), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key pla... mehr

Osteoarthritis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Osteoarthritis - Pipeline Review, H2 2011', provides an overview of the Osteoarthritis therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic... mehr

Osteoporosis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Osteoporosis - Pipeline Review, H2 2011', provides an overview of the Osteoporosis therapeutic pipeline. This report provides information on the therapeutic development for Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic develop... mehr

Psoriatic Arthritis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Psoriatic Arthritis - Pipeline Review, H2 2011', provides an overview of the Psoriatic Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Psoriatic Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involve... mehr

Sarcopenia - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Sarcopenia - Pipeline Review, H2 2011', provides an overview of the Sarcopenia therapeutic pipeline. This report provides information on the therapeutic development for Sarcopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for... mehr

Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H2 2011', provides an overview of the Systemic Juvenile Idiopathic Arthritis (SJIA) therapeutic pipeline. This report provides information on the therapeutic development for Systemic Juvenile Idiopathic Arthritis (SJIA), complete with latest up... mehr

Arthritis - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Arthritis - Pipeline Review, Q3 2011', provides an overview of the Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Art... mehr

Muscle Wasting Disorders - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Muscle Wasting Disorders - Pipeline Review, Q3 2011', provides an overview of the Muscle Wasting Disorders therapeutic pipeline. This report provides information on the therapeutic development for Muscle Wasting Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews... mehr

Arthritis Global Clinical Trials Review, Q2, 2011

Summary

GlobalData's clinical trial report, 'Arthritis Global Clinical Trials Review, Q1, 2011' provides data on the Arthritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Arthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across t... mehr

Cachexia Global Clinical Trials Review, Q2, 2011

Summary

GlobalData's clinical trial report, 'Cachexia Global Clinical Trials Review, Q2, 2011' provides data on the Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the g... mehr

Muscle Spasm - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Muscle Spasm - Pipeline Review, Q2 2011', provides an overview of the Muscle Spasm therapeutic pipeline. This report provides information on the therapeutic development for Muscle Spasm, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic develop... mehr

Muscular Dystrophy - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Muscular Dystrophy - Pipeline Review, Q2 2011', provides an overview of the Muscular Dystrophy therapeutic pipeline. This report provides information on the therapeutic development for Muscular Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in... mehr

Osteopenia Global Clinical Trials Review, Q2, 2011

Summary

GlobalData's clinical trial report, 'Osteopenia Global Clinical Trials Review, Q2, 2011' provides data on the Osteopenia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Osteopenia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction acro... mehr

Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global JRA therapeutics market. The report identifies the key... mehr

Osteoporosis Global Clinical Trials Review, Q1, 2011

Summary

GlobalData's clinical trial report, 'Osteoporosis Global Clinical Trials Review, Q1, 2011' provides data on the Osteoporosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Osteoporosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduct... mehr

Ankylosing Spondylitis Global Clinical Trials Review, Q1, 2011

Summary

GlobalData's clinical trial report, 'Ankylosing Spondylitis Global Clinical Trials Review, Q1, 2011' provides data on the Ankylosing Spondylitis clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Ankylosing Spondylitis. It includes an overview of the trial numbers and their recruitment ... mehr

FDA ends the 50-year long wait for Lupus patients - Benlysta set to become the next blockbuster

Summary

GlobalData’s report, 'FDA ends the 50-year long wait for Lupus patients - Benlysta set to become the next blockbuster” provides key update on the landmark approval of the first lupus drug to be approved by FDA in more than 50 years, HGS/GlaxoSmithKline's Benlysta. It highlights the developmental history of t... mehr

Fragile X Syndrome Global Clinical Trials Review, Q1, 2011

Summary

GlobalData's clinical trial report, 'Fragile X Syndrome Global Clinical Trials Review, Q1, 2011' provides data on the Fragile X Syndrome clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Fragile X Syndrome. It includes an overview of the trial numbers and their recruitment status as per th... mehr

Graft Versus Host Disease (GVHD) Global Clinical Trials Review, Q1, 2011

Summary

GlobalData's clinical trial report, 'Graft Versus Host Disease (GVHD) Global Clinical Trials Review, Q1, 2011' provides data on the Graft Versus Host Disease (GVHD) clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Graft Versus Host Disease (GVHD). It includes an overview of ... mehr

Lupus Nephritis Therapeutics - Pipeline Assessment and Market Forecast to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Lupus Nephritis Therapeutics - Pipeline Assessment and Market Forecast to 2017”. The report is an essential source of information and analysis on the global lupus nephritis therapeutics market. The report identifies the key trends shaping and driving th... mehr

Bone and Joint Infection Market to 2016 - Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment

Summary

GBI Research, the leading business intelligence provider, has released its latest research 'Bone and Joint Infection Market to 2016- Medical Imaging and PCR methods to Facilitate Early Diagnosis and Treatment”, which provides insights into bone and joint infections market sales and price f... mehr

Celiac Disease - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Celiac Disease - Pipeline Review, Q1 2011', provides an overview of the Celiac Disease therapeutic pipeline. This report provides information on the therapeutic development for Celiac Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic... mehr

Crohns Disease - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Crohns Disease - Pipeline Review, Q1 2011', provides an overview of the Crohns Disease therapeutic pipeline. This report provides information on the therapeutic development for Crohns Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic... mehr

Duchenne Muscular Dystrophy - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Duchenne Muscular Dystrophy - Pipeline Review, Q1 2011', provides an overview of the Duchenne Muscular Dystrophy therapeutic pipeline. This report provides information on the therapeutic development for Duchenne Muscular Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It ... mehr

Gout - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Gout - Pipeline Review, Q1 2011', provides an overview of the Gout therapeutic pipeline. This report provides information on the therapeutic development for Gout, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gout. 'Gout - Pipeline ... mehr

Osteoarthritis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Osteoarthritis - Pipeline Review, Q1 2011', provides an overview of the Osteoarthritis therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic... mehr

Osteoporosis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Osteoporosis - Pipeline Review, Q1 2011', provides an overview of the Osteoporosis therapeutic pipeline. This report provides information on the therapeutic development for Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic develop... mehr

Rheumatoid Arthritis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Rheumatoid Arthritis - Pipeline Review, Q1 2011', provides an overview of the Rheumatoid Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players inv... mehr

Systemic Lupus Erythematosus - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Systemic Lupus Erythematosus - Pipeline Review, Q1 2011', provides an overview of the Systemic Lupus Erythematosus therapeutic pipeline. This report provides information on the therapeutic development for Systemic Lupus Erythematosus, complete with latest updates, and special features on late-stage and discontinued projects.... mehr

Ankylosing Spondylitis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Ankylosing Spondylitis - Pipeline Review, Q1 2011', provides an overview of the Ankylosing Spondylitis therapeutic pipeline. This report provides information on the therapeutic development for Ankylosing Spondylitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key pla... mehr

Arthritis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Arthritis - Pipeline Review, Q1 2011', provides an overview of the Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Art... mehr

This report presents a comprehensive update on PD biomarker developments up to 2010. It covers the major classes of emerging and new markers relating to PD (blood, CSF, metabolomic, image-based, genetic and others), and focuses on those investigated in controlled human studies. This includes single and combined markers.



Parkinson's disease (PD) is the second most-common neurodegenerative disorder (after Alzheimer�... mehr

Lung Transplantation - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Lung Transplantation - Pipeline Review, Q1 2011', provides an overview of the Lung Transplantation therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players inv... mehr

Primary Immune Deficiency (PID) - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Primary Immune Deficiency (PID) - Pipeline Review, Q1 2011', provides an overview of the Primary Immune Deficiency therapeutic pipeline. This report provides information on the therapeutic development for Primary Immune Deficiency, complete with latest updates, and special features on late-stage and discontinued projects.... mehr

Osteoarthritis - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist’s new report, 'Osteoarthritis - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global osteoarthritis therapeutics market. The report identifies the key trends shaping and driving the global osteoarthritis therapeutics market. The repo... mehr

Introduction

In 2009, TNF inhibitors were the dominant drug class in terms of sales. However, there is growing use of non-TNF biologics at earlier lines of treatment, and this trend will continue over the next decade. With the first Phase III data from tasocitinib (CP-690,550; Pfizer) reaffirming efficacy with no new safety signals, novel oral small molecules could revolutionize the treatment of RA.
Features and benefits... mehr

Rheumatoid Arthritis - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released a new report, 'Rheumatoid Arthritis - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global rheumatoid arthritis (RA) market. The report identifies the key trends shaping and driving the global RA market.... mehr

Systemic Lupus Erythematosus - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist’s new report, 'Systemic Lupus Erythematosus - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global systemic lupus erythematosus market. The report identifies the key trends shaping and driving the global systemic lupus ... mehr

Arthritis Therapeutics Market to 2016 - Biologics Revolutionize Treatment of Rheumatoid Arthritis and Psoriatic Arthritis

Summary

GBI Research’s new report, 'Arthritis Therapeutics Market to 2016 - Biologics Revolutionize Treatment of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global hepatitis therapeutics market.. Tr... mehr

Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis

Summary

GBI Research’s report, 'Musculoskeletal Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First-in-class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arth... mehr

Osteoporosis - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Osteoporosis - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Osteoporosis therapeutics market. The report identifies the key trends shaping and driving the global Osteoporosis therapeutic... mehr

Introduction

Disease-modifying antirheumatic drugs (DMARDs) underpin the current management of rheumatoid arthritis. This will likely remain unchanged over the next decade. In spite of high costs, rheumatologists perceive there will be an increased penetration of biologic therapies in patients of all severities by 2015, with competition between biologic classes intensifying at earlier lines of therapy.

Scope
<... mehr

Introduction

Disease-modifying antirheumatic drugs (DMARDs) underpin the current management of rheumatoid arthritis. This will likely remain unchanged over the next decade. In spite of high costs, rheumatologists perceive there will be an increased penetration of biologic therapies in patients of all severities by 2015, with competition between biologic classes intensifying at earlier lines of therapy.

Scope
<... mehr

Introduction

Globally, the osteoporosis market displayed a 3.5% compound annual growth rate (CAGR) between 2005—09, reaching $9.4 billion in 2009. However, the launch of generic alendronate in the majority of markets resulted in a temporary decline in sales during 2009. The market will stabilize during the next 5 years due to generic incursion and then resume growth from 2015 as new drugs are launched.

Scope<... mehr

Introduction

Osteoporosis continues to be an attractive therapy area for large pharmaceutical companies due to its high prevalence rate and unmet need. Across the seven major markets, sales for osteoporosis drugs grew with a compound annual growth rate (CAGR) of 2.0% from 2005 to $6.9 billion in 2009. Nonetheless, several promising pipeline drugs will help the market resume growth.

Scope

*Patient potenti... mehr

Cough, cold and allergy remedies drove the consumer healthcare market in 2009, accounting for 22% of value sales. Combination products, which target more than one symptom, lead this category, with value sales worth Do$298 million in 2009. This represented 50% of cough, cold and allergy remedies’ total value.

Euromonitor International's Cough, Cold and Allergy (Hay Fever) Remedies Products in Dominican Republic report offers... mehr

Life Science Analytics', Arthritis Therapy Area Pipeline Report contains detailed information on the arthritis drug pipeline. This report provides insight into the pipeline status of arthritis drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug ... mehr

Life Science Analytics', Atherosclerosis Therapy Area Pipeline Report contains detailed information on the atherosclerosis drug pipeline. This report provides insight into the pipeline status of atherosclerosis drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with re... mehr

Life Science Analytics', Autoimmune Diseases Therapy Area Pipeline Report contains detailed information on the autoimmune diseases drug pipeline. This report provides insight into the pipeline status of autoimmune diseases drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the ... mehr

Life Science Analytics', Gout Therapy Area Pipeline Report contains detailed information on the gout drug pipeline. This report provides insight into the pipeline status of gout drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by c... mehr

Life Science Analytics', Multiple Sclerosis Therapy Area Pipeline Report contains detailed information on the multiple sclerosis drug pipeline. This report provides insight into the pipeline status of multiple sclerosis drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the use... mehr

Life Science Analytics', Osteoarthritis Therapy Area Pipeline Report contains detailed information on the osteoarthritis drug pipeline. This report provides insight into the pipeline status of osteoarthritis drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real ... mehr

Life Science Analytics', Osteoporosis Therapy Area Pipeline Report contains detailed information on the osteoporosis drug pipeline. This report provides insight into the pipeline status of osteoporosis drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail... mehr

Life Science Analytics', Postmenopausal Osteoporosis Therapy Area Pipeline Report contains detailed information on the postmenopausal osteoporosis drug pipeline. This report provides insight into the pipeline status of postmenopausal osteoporosis drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipel... mehr

Osteoarthritis - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData, the industry analysis specialist’s new report, 'Osteoarthritis — Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global osteoarthritis market. The report identifies the key trends shaping and driving the global osteoarthritis market. The report also provid... mehr

Muscular Dystrophy - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData, the industry analysis specialist’s new report, 'Muscular dystrophy — Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global muscular dystrophy market. The report identifies the key trends shaping and driving the global muscular dystrophy market. The re... mehr

Introduction

Datamonitor expect osteoarthritis prevalence to grow by over 10 million by 2020, owing mainly to an aging population. In the near-term the approach to treatment will remain constant, with improved side-effects dominating the unmet needs. However, therapies which target the underlying causes of osteoarthritis have the potential to reshape osteoarthritis treatment.

Scope

*Snapshot of the osteo... mehr

Introduction

Datamonitor expect osteoarthritis prevalence to grow by over 10 million by 2020, owing mainly to an aging population. In the near-term the approach to treatment will remain constant, with improved side-effects dominating the unmet needs. However, therapies which target the underlying causes of osteoarthritis have the potential to reshape osteoarthritis treatment.

Scope

*Snapshot of the osteo... mehr

Introduction

The growing recognition from companies of the applied benefits from biomarkers in rheumatology has spurred commercial interest in this field. Despite the lack of major advancements, the hope remains that soon rheumatologists will be able to predict response to expensive biologic therapies and match specific treatments to patients based upon biomarker profiles.

Scope

*Classification and overv... mehr

Summary

GBI Research, the leading business intelligence provider, has released its latest research 'The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis. The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global autoimmune diseases therapeutics market. The report analyzes the markets for autoimmune disea... mehr

Summary

GBI Research, the leading business intelligence provider, has released its latest research 'The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis. The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global monoclonal antibodies market. The report analyzes the markets for monoclonal antibodies in the US, the t... mehr

REPORT DESCRIPTION

Autoimmune disorders result from an overactive immune response of a body working against its own cells. The disease is broadly classified into two types: systemic autoimmune diseases, which affect several organs of the body; and localized autoimmune diseases, which affect only one organ. Around 80 autoimmune diseases are recognized under these two categories. The disease affected over 300 million people acr... mehr

Introduction

Osteoporosis continues to be an attractive therapy area for large pharmaceutical companies due to its high prevalence rate and unmet need. Globally, sales for osteoporosis drugs grew 7.0% year-on-year from 2004 to $9.6 billion in 2008 driven by strong performance of the bisphosphonate class.

Scope

* Patient potential analysis across the seven major markets and BRIC nations (Brazil, Russi... mehr

Only about 36% of Multiple Sclerosis (MS) patients are currently treated with MS drugs, this percentage is expected to increase to 56% by 2014 as new oral MS therapies are launched, which shows bright opportunity for oral drugs in multiple sclerosis market. The injectables market is big but leaves certain side effects which bring the possibility for the oral drugs to succeed. It is expected that oral drugs will bring some ease for the p... mehr

Introduction

Factors influencing a prescribing decision can diverge from clinical facts. In the highly competitive autoimmune area, misconceptions and physician habits can result in loss of sales. Targeted detailing of specialist physicians, differentiating by indications is the key to success. Datamonitor has surveyed gastroenterologists, rheumatologists and dermatologists on attribute and brand perceptions

Scope<... mehr

Introduction

Psoriatic arthritis and ankylosing spondylitis form part of the group of diseases known as the spondyloarthropathies. Psoriatic arthritis is a form of inflammatory arthritis associated with psoriasis, whilst ankylosing spondylitis causes arthritis of the spine and sacroiliac joints. Moderate-severe disease for both patient groups is frequently treated with similar therapies, including biologics.

Scope<... mehr

Introduction

Despite forming the mainstay of pharmacological treatment of anxiety disorders, response rates to serotonergic-based treatments are often less than robust. As such, physicians are increasingly looking towards novel drugs. For pharmaceutical companies, the pressure to meet this need and maintain market share is growing as the patent expiries of three major brands draws near.

Scope

*Analysis o... mehr

Life Science Analytics', 'Autoimmune And Inflammation Arthritis ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug p... mehr

Life Science Analytics', 'Autoimmune And Inflammation Autoimmune Diseases ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail... mehr

Life Science Analytics', 'Autoimmune And Inflammation Lupus ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipel... mehr

Life Science Analytics', 'Autoimmune And Inflammation Rheumatoid Arthritis ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detai... mehr

Life Science Analytics', 'Central Nervous System Multiple Sclerosis ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on dr... mehr

Life Science Analytics', 'Musculo-Skeletal-Disorders Gout ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelin... mehr

Life Science Analytics', 'Musculo-Skeletal-Disorders Muscle Pain ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug ... mehr

Life Science Analytics', 'Musculo-Skeletal-Disorders Osteoarthritis ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on dr... mehr

Life Science Analytics', 'Musculo-Skeletal-Disorders Osteoporosis ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug... mehr